Kawasaki disease emerges as a model for decoding childhood inflammatory disorders

Kawasaki disease has long been a puzzle for paediatric medicine, but a new editorial published in Pediatric Research argues that the condition should now be viewed as a prototypic disorder for understanding the entire spectrum of childhood inflammatory disease. Written by Eleanor J. Molloy of Trinity College Dublin, Cynthia Bearer of Case Western Reserve University, and Seigo Okada of Yamaguchi University and Boston Children’s Hospital, the editorial traces how the field has moved beyond the simple division between autoimmune and autoinflammatory conditions toward an integrated framework in which innate and adaptive immune pathways intersect. The authors contend that lessons drawn from Kawasaki disease, multisystem inflammatory syndrome in children (MIS-C), and even the COVID-19 pandemic are converging on a single conclusion: precision medicine, guided by biomarkers and genetic susceptibility, is the future of treating paediatric hyperinflammation.

Kawasaki disease, first described by the Japanese paediatrician Tomisaku Kawasaki in 1967 and originally termed mucocutaneous lymph node syndrome, remains the most common cause of acquired heart disease in children in developed countries. Its impact extends well beyond the acute febrile illness, as families navigate diagnostic uncertainty, treatment challenges, and lasting emotional burden, an experience vividly documented in a parental reflection published in the same journal. Over nearly six decades, the disorder has evolved from a clinicopathological syndrome defined by fever, rash, mucosal changes, and lymphadenopathy into a key model for studying dysregulated innate immune responses and vasculitis. Advances in immunology, genetics, and systems biology have progressively repositioned it at the centre of paediatric inflammatory research, making it a lens through which other conditions can be understood.

The conceptual turning point came in 2006, when McGonagle and McDermott proposed that many inflammatory diseases are driven predominantly by innate immune dysregulation rather than adaptive autoimmune responses. Two decades later, that proposal has matured into a classification framework acknowledging substantial overlap among autoimmune, autoinflammatory, and hyperinflammatory conditions. Kawasaki disease displays many classical hallmarks of autoinflammation: acute systemic inflammation, activation of innate immune pathways, elevated cytokine production, and neutrophil predominance during the acute phase. Yet adaptive immune responses also contribute to the vascular injury that makes the disease so dangerous, illustrating the continuum that modern classification systems now recognise. This framework is especially relevant in paediatrics, where many severe inflammatory syndromes follow infectious triggers in genetically susceptible children.

Immune responses, the editorial emphasises, vary dramatically with age. The neonatal immune system is characterised by mechanisms that balance pathogen defence against protection from excessive inflammation, and immune function progressively shifts from birth through childhood, producing inflammatory profiles distinct from those of adults. Research by Olin and colleagues demonstrated that immune system development follows stereotypic trajectories in early life, while Jeljeli and colleagues showed age-dependent changes in cytokine responses, with a gradual progression from anti-inflammatory dominance in newborns toward more balanced T-helper responses during childhood. These developmental differences may explain variations in susceptibility, severity, and outcomes across inflammatory disorders and sepsis. Paediatric septic shock, for example, shows significant age-related transcriptomic differences involving neutrophils, monocytes, and lymphocytes, suggesting that developmental immunology plays a central role in disease pathogenesis rather than being a peripheral consideration.

The COVID-19 pandemic sharpened these insights into age-dependent immunity. Children appeared relatively protected from severe acute SARS-CoV-2 infection despite widespread exposure, even as hyperinflammatory conditions such as MIS-C increased in areas of high viral prevalence. The editorial attributes this reduced severity to several converging mechanisms: altered inflammatory responses, differences in angiotensin-converting enzyme 2 expression, endotoxin tolerance, and developmental immune programming. These observations support the broader concept that age-dependent immune responses govern susceptibility to hyperinflammatory disorders and provide a useful framework for understanding both Kawasaki disease and MIS-C. The pandemic thus served as an unplanned natural experiment, revealing how the same pathogen can produce mild disease in most children yet trigger catastrophic immune dysregulation in a vulnerable subset.

At the molecular level, the editorial highlights the NLRP3 inflammasome as a central regulator of inflammatory responses across many immune-mediated diseases in newborns and children. Inflammasome activation drives production of the pro-inflammatory cytokines interleukin-1β and interleukin-18, amplifying systemic inflammation and contributing to tissue damage. Tate and Mansell have underscored the critical role of NLRP3 signalling in severe viral inflammatory responses, while Xue and colleagues demonstrated that microRNA-mediated regulation of NLRP3 activation contributes to pyroptosis, the inflammatory form of cell death, and to endotoxic shock. Inflammasome pathways also mediate vasculitis, autoinflammatory conditions, and cardiovascular inflammation, making them attractive therapeutic targets for novel immunomodulatory interventions. The editorial also reaches back more than a century to George Bernard Shaw’s The Doctor’s Dilemma, noting that early concepts of individualised immunotherapy align closely with modern precision medicine approaches targeting specific inflammatory pathways.

The emergence of MIS-C during the pandemic created a unique opportunity to compare two paediatric inflammatory syndromes with overlapping features. Both share fever, elevated inflammatory markers, cardiovascular involvement, and cytokine dysregulation, but they diverge in important ways. MIS-C is associated with greater systemic inflammation, higher rates of myocardial dysfunction, and more prominent cytokine activation, whereas Kawasaki disease is characterised by coronary artery involvement and classic mucocutaneous manifestations. Detailed immunophenotyping of children with MIS-C revealed significant alterations in both innate and adaptive immunity: neutrophils and monocytes showed activation markers including CD11b and toll-like receptor 4, serum cytokine analysis revealed increased levels of interleukin-6, interleukin-10, tumour necrosis factor-β, and vascular endothelial growth factor, and patients exhibited neutrophilia, an elevated neutrophil-to-lymphocyte ratio, and lymphopenia. Following lipopolysaccharide stimulation, TNF-β responses remained exaggerated while interleukin-1 receptor antagonist and erythropoietin levels were consistently reduced, alongside reductions in CD3-positive T cells, natural killer cells, and Vδ1 T-cell receptor cells with a relative increase in B lymphocytes.

These findings position MIS-C, the neonatal variant MIS-N, and Kawasaki disease at related points along a spectrum of post-infectious inflammatory disorders characterised by varying degrees of innate immune activation, cytokine dysregulation, endothelial dysfunction, and cardiovascular involvement. In both conditions, infectious triggers can initiate dysregulated inflammatory responses in genetically susceptible individuals, and insights from each have improved understanding of disease classification and potential therapeutic targets. The comparison has practical consequences: clinicians must distinguish between syndromes that may look superficially similar but differ in myocardial dysfunction, coagulopathy, and coronary risk, and immunomodulatory strategies should aim at restoring immune homeostasis rather than simply suppressing inflammation indiscriminately.

Treatment resistance remains one of the field’s most pressing clinical challenges. Rapidly administered intravenous immunoglobulin is the international standard of care for acute Kawasaki disease, yet approximately 10 to 20 percent of patients demonstrate resistance to the therapy and face an increased risk of developing coronary artery abnormalities. Lam and colleagues applied machine learning techniques to more than 7,800 patients, using clinical, laboratory, and echocardiographic variables visualised through uniform manifold approximation and projection, a high-dimensional data technique. Although predictive performance improved compared with conventional scoring systems, the authors concluded that clinically useful prediction models will likely require the incorporation of genetic, transcriptomic, proteomic, or novel biomarker data. Accurately identifying treatment-resistant patients remains an unmet need, because earlier intensification of anti-inflammatory therapy could reduce cardiovascular complications, although none of these alternative therapies are yet standard of care.

The editorial closes with a vision of precision immunotherapy that depends on identifying the optimal timing and the patient populations most likely to respond. Targeted therapies directed against tumour necrosis factor, interleukin-1, and interleukin-6 pathways have shown efficacy in selected hyperinflammatory syndromes, but because inflammatory responses are dynamic and progressive, longitudinal immune monitoring and biomarker-guided treatment strategies are essential. Integrating transcriptomic, proteomic, metabolomic, and genomic data is likely to refine both disease classification and therapeutic targeting across the spectrum of paediatric inflammatory disorders. For a disease that has puzzled clinicians since 1967, Kawasaki disease now occupies a unique position: no longer merely a diagnostic challenge, it has become a valuable model through which the mechanisms distinguishing protective immunity from pathological hyperinflammation can be investigated, with the ultimate goal of improving outcomes for children worldwide.

Subject of Research: Kawasaki disease as a model for classifying paediatric multisystem inflammatory disorders

Article Title: Kawasaki disease: a primer for the classification of multisystem inflammatory disorders

Article References: Molloy, E. J., Bearer, C., & Okada, S. (2026). Kawasaki disease: a primer for the classification of multisystem inflammatory disorders. Pediatric Research. https://doi.org/10.1038/s41390-026-05573-5

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05573-5

Keywords: Kawasaki disease, MIS-C, hyperinflammation, autoinflammation, innate immunity, NLRP3 inflammasome, intravenous immunoglobulin resistance, paediatric vasculitis, COVID-19, precision medicine, cytokine storm, developmental immunology